Alkem Laboratories Limited has announced the appointment of Dr. Amrut Naik as its new Chief Executive Officer (CEO). Dr. Naik, a seasoned global pharmaceutical leader with over 26 years of experience, will assume his new role with effect from November 11, 2026. This strategic leadership change is expected to steer the company’s future growth and expansion initiatives, leveraging his extensive expertise in various pharmaceutical business segments.
Leadership Transition at Alkem Laboratories
Alkem Laboratories Limited has officially announced a significant leadership change, with the appointment of Dr. Amrut Naik as the new Chief Executive Officer (CEO) and Key Managerial Personnel. This decision was made by the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, and is effective from November 11, 2026.
Dr. Amrut Naik’s Extensive Experience
Dr. Amrut Naik brings a wealth of experience to Alkem Laboratories, boasting over 26 years of global pharmaceutical business leadership. His expertise spans building, scaling, and transforming businesses across various domains including Branded Formulations, Generics, APIs, Biologics, Vaccines, Specialty, and Innovation-led portfolios. Academically, Dr. Naik holds a Ph.D. (Tech) in Pharmacology, a Master’s in Pharmaceutical Science, and a Bachelor’s in Pharmaceutical Science, equipping him with a strong foundation for strategic leadership.
Further Details
As required by regulatory disclosures, detailed information pertaining to Dr. Naik’s appointment, including the terms of his engagement, is provided in Annexure I to this letter. The company has also made this information available on its official website, www.alkemlabs.com.
Source: BSE
